Clinical and in vitro studies reinforce this assertion as the administration of an anti-CD200 monoclonal antibody to block CD200/CD200R signaling was shown to be sufficient in reducing Treg frequencies for chronic lymphocytic leukemia patients and cell samples [55,56]. Here, CD200 is linked to B-cell chronic lymphocytic leukemia.